Bristol-Myers Squibb Co vs Nerdwallet Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Nerdwallet Inc trades at $9.78 (market cap $625.17M). The key difference: Bristol-Myers Squibb Co is far larger — about 207.8× Nerdwallet Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| BMY | NRDS | |
|---|---|---|
Market Cap | $129.94B | $625.17M |
Sector | Health | Financials |
52-Week High | $65.89 | $15.93 |
52-Week Low | $42.60 | $7.58 |
Enterprise Value | $163.92B | $539.47M |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →